+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5181442
  • Report
  • October 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
UP TO OFF
until Dec 31st 2020

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • Dilion Technologies Inc
  • Gamma Medica Inc
  • Hologic Inc
  • Micrima Limited
  • MORE
Breast Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global breast cancer diagnostics market.

This report focuses on breast cancer diagnostics market which is experiencing strong growth. The report gives a guide to the breast cancer diagnostics market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pand emic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the breast cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Breast Cancer Diagnostics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive land scape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider breast cancer diagnostics market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive land scape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The breast cancer diagnostics market section of the report gives context. It compares the breast cancer diagnostics market with other segments of the breast cancer diagnostics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, breast cancer diagnostics indicators comparison.
Scope

Markets Covered:
1)By Type: Imaging; Biopsy; Genomic Tests; Blood Tests; Others
2) By Technology: Fluorescent In Situ Hybridization (FISH); Comparative Genomic Hybridization (CGH); Immunohistochemical (IHC); Other Technologies
3) By Cancer Type: BRCA Breast Cancer; ER & PR Breast Cancer; HER 2 Breast Cancer; EGFR Mutation Test Breast Cancer; Others
4) By Diagnostic Type: Ionizing Breast Imaging Technologies; Non-ionizing Imaging Technologies
5) By End Users: Hospitals and Clinics; Cancer Research Centers; Diagnostic Laboratories; Ambulatory Surgical Centers

Companies Mentioned: Abbott Laboratories; Myriad Genetics, Inc.; Hologic, Inc.; Koninklijke Philips N.V.; Fujifilm Holdings Corporation

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • Dilion Technologies Inc
  • Gamma Medica Inc
  • Hologic Inc
  • Micrima Limited
  • MORE
1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Size And Growth
3.1. Global Breast Cancer Diagnostics Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Breast Cancer Diagnostics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Breast Cancer Diagnostics Market Segmentation
4.1. Global Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others
4.2. Global Breast Cancer Diagnostics Market, Segmentation By Technology, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Fluorescent In Situ Hybridization (FISH)
  • Comparative Genomic Hybridization (CGH)
  • Immunohistochemical (IHC)
  • Other Technologies
4.3. Global Breast Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • BRCA Breast Cancer
  • ER & PR Breast Cancer
  • HER 2 Breast Cancer
  • EGFR Mutation Test Breast Cancer
  • Others
4.4. Global Breast Cancer Diagnostics Market, Segmentation By Diagnostic Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Ionizing Breast Imaging Technologies
  • Non-ionizing Imaging Technologies
4.5. Global Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospitals and Clinics
  • Cancer Research Centers
  • Diagnostic Laboratories
  • Ambulatory Surgical Centers
5. Breast Cancer Diagnostics Market Regional And Country Analysis
5.1. Global Breast Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Breast Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Breast Cancer Diagnostics Market
6.1. Asia-Pacific Breast Cancer Diagnostics Market Overview
6.2. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Breast Cancer Diagnostics Market
7.1. China Breast Cancer Diagnostics Market Overview
7.2. China Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Breast Cancer Diagnostics Market
8.1. India Breast Cancer Diagnostics Market Overview
8.2. India Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Breast Cancer Diagnostics Market
9.1. Japan Breast Cancer Diagnostics Market Overview
9.2. Japan Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Breast Cancer Diagnostics Market
10.1. Australia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Breast Cancer Diagnostics Market
11.1. Indonesia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Breast Cancer Diagnostics Market
12.1. South Korea Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Breast Cancer Diagnostics Market
13.1. Western Europe Breast Cancer Diagnostics Market Overview
13.2. Western Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Breast Cancer Diagnostics Market
14.1. UK Breast Cancer Diagnostics Market Overview
14.2. UK Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Breast Cancer Diagnostics Market
15.1. Germany Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Breast Cancer Diagnostics Market
16.4. France Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Breast Cancer Diagnostics Market
17.1. Eastern Europe Breast Cancer Diagnostics Market Overview
17.2. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Breast Cancer Diagnostics Market
18.1. Russia Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Breast Cancer Diagnostics Market
19.1. North America Breast Cancer Diagnostics Market Overview
19.2. North America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Breast Cancer Diagnostics Market
20.1. USA Breast Cancer Diagnostics Market Overview
20.2. USA Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Breast Cancer Diagnostics Market
21.1. South America Breast Cancer Diagnostics Market Overview
21.2. South America Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Breast Cancer Diagnostics Market
22.1. Brazil Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Breast Cancer Diagnostics Market
23.1. Middle East Breast Cancer Diagnostics Market Overview
23.2. Middle East Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Breast Cancer Diagnostics Market
24.1. Africa Breast Cancer Diagnostics Market Overview
24.2. Africa Breast Cancer Diagnostics Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Breast Cancer Diagnostics Market, Segmentation By End Users, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles
25.1. Breast Cancer Diagnostics Market Competitive Landscape
25.2. Breast Cancer Diagnostics Market Company Profiles
25.2.1. Abbott Laboratories
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Myriad Genetics Inc
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Hologic Inc
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Koninklijke Philips N.V.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Fujifilm Holdings Corporation
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Breast Cancer Diagnostics Market

27. Breast Cancer Diagnostics Market Trends And Strategies

28. Breast Cancer Diagnostics Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • Dilion Technologies Inc
  • Gamma Medica Inc
  • Hologic Inc
  • Micrima Limited
  • MORE
Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc, Hologic Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc, Siemens AG, NanoString Technologies Inc., and C. R. Bard Inc.

The global breast cancer diagnostics market is expected to decline from $4.88 billion in 2019 to $4.62 billion in 2020 at a compound annual growth rate (CAGR) of -5.38%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, especially postponement of non-emergency procedures. The market is then expected to recover and reach $6.32 billion in 2023 at a CAGR of 10.99%.

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce breast cancer diagnostics devices. These devices are used to diagnose breast cancer. Only goods and services traded between entities or sold to end consumers are included.

North America was the largest region for breast cancer diagnostics market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

The technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In March 2019, Southwest Medical Center, a US-based company, launched 3D mammography services that provide patients with access to enhanced breast imaging services closer to home.

The breast cancer diagnostics market covered in this report is segmented by type into imaging; biopsy; genomic tests; blood tests; others. It is also segmented by technology into fluorescent in situ hybridization (FISH); comparative genomic hybridization (CGH); immunohistochemical (IHC); other technologies, by cancer type into BRCA breast cancer; ER & PR breast cancer; HER 2 breast cancer; EGFR mutation test breast cancer; others, by diagnostic type into ionizing breast imaging technologies; non-ionizing imaging technologies, and by end users into hospitals and clinics; cancer research centers; diagnostic laboratories; ambulatory surgical centers.

The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to a 2019 study conducted by Mesothelioma Center, around 63% of respondents that comprise of people with cancer and their family members reported financial difficulties. For instance, the total cost of diagnosis for breast cancer was $353 per patient but diagnostic costs varied from $151 in some regions to $751 in others. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market.

In November 2019, EXACT Sciences Corporation, a US-based molecular diagnostics company, acquired Genomic Health for $2.8 billion. Through this acquisition, Exact Sciences will be able to facilitate therapy decisions for colorectal, breast and prostate cancers by Genomic Health’s Oncotype DX gene expression. Genomic Health is a US-based genomic diagnostics manufacturer.

The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and furthermore causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of all cancer deaths in women. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market.
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Myriad Genetics Inc
  • Hologic Inc
  • Koninklijke Philips N.V.
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • Thermo Fischer Scientific Inc
  • Siemens AG
  • NanoString Technologies Inc
  • C. R. Bard Inc
  • Gamma Medica Inc
  • Aurora Imaging Technology Inc
  • Dilion Technologies Inc
  • Genomic Health
  • F. Hoffmann-La Roche Ltd
  • Micrima Limited
  • Provista Diagnostics Inc
  • Leica Biosystems Nussloch GmbH
  • bioTheranostics Inc
  • Bio-Rad Laboratories Inc
  • Illumina Inc
  • Biocept Inc
  • Epigenomics AG
  • AstraZeneca plc
  • Quest Diagnostics Incorporated
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll